eyeforpharma.com

ROI & Analytics

The elusive win/win – Is value capture a problem for pharma?

Apr 30, 2008

A pig and a chicken agreed to meet for breakfast. The chicken said, “We should both contribute something for breakfast. I’ll bring the eggs and you bring the bacon”.

How can blogs be utilized in online Rx communication?

Apr 29, 2008

In many European countries, the advertising of prescription drugs is severely regulated, often to the point where the brand name of a medicine cannot be mentioned in any campaign, including in adverti

A different kind of DTCA

As David Impey, consultant for BigBear Communications points out, the environments for direct to consumer advertising (DTCA) in Europe and in the United States are very different.

(Nov 20, 2007)

Paying attention to ROI analytics

Just how important is it to understand how much you’re spending on sales and marketing and where exactly that money is going?

(Nov 20, 2007)

Individualism and consumerism in UK healthcare

“Even though we have a state-provided system, individuals should still be able to express some choice about whether or not they want particular treatments,” he says.

(Oct 9, 2007)

Using target marketing to improve patient compliance

Patient non-compliance with prescription therapies represents significant lost revenue to pharmaceutical makers.

(May 27, 2007)

Improving patient compliance with low-cost wireless technologies

According to Datamonitor, patient non-adherence costs the pharmaceutical industry in excess of $30 billion a year.

(Oct 11, 2006)

Faster can be better - for the bottom line

According to Tufts, drug companies that develop and launch new products faster than their competitors perform consistently better across a range of dimension, earn higher revenues and have lower devel

(Sep 26, 2006)

Is more money the answer to improved drug safety monitoring?

Researchers at Duke University and the University of North Carolina at Chapel Hill estimate that in 2003 the top 20 pharmaceutical manufacturers spent a total of $800 million, or 0.3 % of sales, on dr

(Mar 9, 2006)

Can pharma find new solutions to some old problems in 2006?

For an industry that once seemed immune to the ebb and flow of the economy and was highly regarded by the public, 2005 was a particularly tough year.

(Jan 4, 2006)